查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1950541

标靶治疗黑色素瘤治疗市场：按作用机制、给药途径、治疗线、分销管道和最终用户划分－全球预测，2026-2032年

Targeted Therapy Drugs for Melanoma Market by Mechanism Of Action, Route Of Administration, Treatment Line, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，黑色素瘤标靶治疗市场价值将达到 74.2 亿美元，到 2026 年将成长至 80.6 亿美元，复合年增长率为 9.32%，到 2032 年将达到 138.6 亿美元。

关键市场统计数据
基准年 2025 74.2亿美元
预计年份：2026年 80.6亿美元
预测年份 2032 138.6亿美元
复合年增长率 (%) 9.32%

简明扼要而又全面地介绍了分子标靶治疗和免疫调节如何重新定义黑色素瘤治疗的临床策略和商业性动态。

分子标靶治疗将分子生物学与治疗目标结合，重塑了黑色素瘤的临床治疗模式。过去十年，致癌性通路抑制剂和免疫查核点调节剂的进步，使治疗方法从「一刀切」式转变为精准治疗，从而更好地应对肿瘤异质性和抗药性机制。本入门指南整合了定义黑色素瘤分子标靶说明现状的科学原理、不断发展的临床实践和商业性趋势。

客观地检验分子诊断、联合治疗策略和支付方预期如何重塑黑色素瘤治疗的临床实践和商业模式

在科学突破、监管先例和不断发展的临床实践的推动下，黑色素瘤的治疗模式发生了变革性变化。分子诊断和次世代定序的创新使得BRAF突变疾病和其他可治疗的基因改变能够被精准识别，从而使临床医生能够更一致、更恰当地选择适合BRAF和MEK抑制剂治疗的患者。同时，标靶CTLA-4和PD-1通路免疫查核点抑制剂为多种患者群体带来持久疗效奠定了基础，促使人们重新评估何时以及如何应用标靶药物和免疫疗法。

2025年美国关税调整对黑色素瘤药物供应链、采购惯例和临床取得的影响策略分析

贸易政策趋势和关税调整有可能对全球药品供应链、生产经济和分销策略产生不成比例的影响。到2025年，美国关税政策的变化可能会透过多个相互关联的途径影响黑色素瘤治疗生态系统，从上游原料药采购到下游分销成本以及医院系统的采购行为。

从多维度细分观点，将黑色素瘤治疗中的临床和商业性需求与作用机制、给药途径、治疗方案、通路和临床环境联繫起来。

要了解市场，需要根据作用机制、给药途径、治疗线、分销管道和最终用户进行细緻的细分，因为每个维度都会影响不同的临床决策点、商业性槓桿和营运挑战。依作用机制，治疗方法可分为BRAF抑制剂、CTLA-4抑制剂、MEK抑制剂和PD-1抑制剂。 BRAF抑制剂包括Dabrafenib、Encorafenib和Vemurafenib等药物；CTLA-4抑制剂包括Ipilimumab；MEK抑制剂包括比美替尼、Cobimetinib替尼和Trametinib；PD-1抑制剂包括Nivolumab和Pembrolizumab。每种分子类别对患者选择、毒性管理和联合治疗策略都有不同的影响，它们的竞争动态也反映了专利状态、适应症和临床成熟度的差异。

区域情报简报重点介绍美洲、欧洲、中东和非洲以及亚太地区独特的监管、报销和准入趋势及其战略影响。

区域趋势在靶向黑色素瘤疗法的可及性、监管策略和商业性优先顺序的製定中发挥关键作用。在美洲，完善的法规结构和精准诊断的高普及率促进了已通过核准的标靶治疗和免疫疗法的快速应用，但支付方覆盖范围和各州采购政策的差异可能导致可及性不均衡。因此，在该地区运营的製造商必须解决诊断可及性方面的差异，同时调整其报销申请和真实世界证据的生成，以满足区域支付方的期望。

对领先的生物製药公司如何利用转化科学、诊断伙伴关係和供应链韧性来保持其在黑色素瘤治疗领域的领先地位进行了深入评估。

黑色素瘤标靶治疗领域的主要企业融合了深厚的临床经验、专注的研发投入和策略联盟。业界领导者正利用强大的转化平台推动新型BRAF和MEK抑制剂的研发，同时大力投资免疫肿瘤学项目，以补充标靶治疗。许多公司采用联合疗法开发模式，将激酶抑制剂与查核点抑制剂合併使用，以克服抗药性机制并提高疗效的持久性。

一套切实可行的、优先排序的策略行动方案，旨在帮助药物研发者、支付者和医疗服务提供者将临床突破转化为可持续的患者疗效和商业性可行性。

产业领导者应采取一系列有针对性的行动，使科学研究机会与商业性现实相契合。首先，将临床开发与稳健的生物标记策略相结合至关重要，这有助于最大限度地识别有效应答者，并支持与支付方进行价值评估。申办者应设计能够捕捉肿瘤反应、持久性和生活品质（QOL）终点的试验，这些终点对临床医生和支付者都至关重要。其次，基于明确机制的联合治疗可以扩大临床效益，但这些方案必须整合毒性缓解计画和实际应用路径。

本执行摘要的调查方法是一种混合方法，结合了专家访谈、文献检验和三角综合分析，以透明的方式呈现可靠的研究结果。

本执行摘要的调查方法结合了质性检验、严谨的二手资料验证和迭代三角测量分析。定性研究包括对临床研究人员、肿瘤药剂师、医院药房经理和高阶主管进行深度访谈，以确定实际应用中的驱动因素、营运限制和未满足的需求。二手资料研究则利用同侪审查文献、监管指导文件、临床试验註册库和公司备案文件，建构全面的证据基础，并检验从质性访谈中得出的结论。

这份简明扼要的概述将分子创新、诊断整合和运作准备联繫起来，为加速黑色素瘤治疗中患者获益提供了一条切实可行的途径。

总之，目前黑色素瘤标靶治疗处于分子精准医学和免疫调节的交叉领域，这给相关人员带来了复杂而又切实的策略挑战。 BRAF和MEK抑制剂以及CTLA-4和PD-1路径调节技术的进步已经建立了多种治疗平台，而对联合疗法的重新关注旨在扩大每种治疗方法的益处，同时控制重迭的毒性。在商业性，诊断、证据产生和供应稳定性的整合将决定哪些项目能够成功，哪些项目难以实现广泛且公平的可近性。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 依作用机转分類的标靶治疗市场

  • BRAF抑制剂
    • Dabrafenib
    • Encorafenib
    • Vemurafenib
  • CTLA-4抑制剂
  • MEK抑制剂
    • 比美替尼
    • Cobimetinib
    • Trametinib
  • PD-1抑制剂
    • Nivolumab
    • Pembrolizumab

9. 按给药途径标靶治疗市场

  • 静脉注射
  • 口服

10. 按治疗线标靶治疗市场

  • 一线治疗
  • 二级治疗
  • 三线及以后

第十一章标靶治疗市场（按分销管道划分）

  • 医院药房
  • 网路药房
  • 零售药房

第十二章标靶治疗市场（依最终用户划分）

  • 门诊手术中心
  • 医院
  • 肿瘤中心

13. 各地区标靶治疗市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章标靶治疗市场（按组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

15. 各国标靶治疗市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

16. 美国标靶治疗市场

第十七章：中国黑色素瘤标靶治疗药物市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Amgen Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Bristol Myers Squibb Company
  • Eli Lilly and Company
  • GlaxoSmithKline plc
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Roche Holding AG
  • Sanofi SA
Product Code: MRR-4F7A6D4FD8CC

The Targeted Therapy Drugs for Melanoma Market was valued at USD 7.42 billion in 2025 and is projected to grow to USD 8.06 billion in 2026, with a CAGR of 9.32%, reaching USD 13.86 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 7.42 billion
Estimated Year [2026] USD 8.06 billion
Forecast Year [2032] USD 13.86 billion
CAGR (%) 9.32%

A concise yet comprehensive primer that explains how molecular targeting and immune modulation have redefined clinical strategy and commercial dynamics in melanoma treatment

Targeted therapy has reshaped the clinical approach to melanoma by aligning molecular biology with therapeutic intent. Over the past decade, advances in oncogenic pathway inhibitors and immune checkpoint modulation have replaced one-size-fits-all paradigms with precision strategies that address tumor heterogeneity and resistance mechanisms. This introduction synthesizes the scientific principles, clinical practice shifts, and commercial dynamics that define the current landscape of targeted therapies for melanoma.

At the molecular level, actionable mutations such as BRAF V600 and alterations in downstream MAPK signaling have provided clear targets for small-molecule inhibitors. Concurrently, immune-oncology agents that release inhibitory brakes on T cells have transformed long-term disease control for many patients. The interplay between targeted agents and immunotherapies now defines treatment sequencing, combinatorial regimens, and toxicity management. Clinicians and payers increasingly demand evidence of durable benefit and manageable safety profiles, prompting more rigorous comparative evaluations and biomarker-driven patient selection. As a result, commercialization strategies have evolved to emphasize companion diagnostics, value-based contracting, and real-world evidence generation.

This introduction frames the subsequent sections by highlighting how mechanistic innovation, regulatory evolution, and shifting commercial imperatives converge to create both opportunity and complexity for stakeholders across the melanoma care continuum.

A clear-eyed examination of how molecular diagnostics, combination strategies, and payer expectations are reshaping clinical practice and commercialization approaches in melanoma care

The melanoma treatment landscape has undergone transformative shifts driven by scientific breakthroughs, regulatory precedent, and evolving clinical practice. Innovations in molecular diagnostics and next-generation sequencing have enabled precise identification of BRAF-mutant disease and other actionable alterations, allowing clinicians to match patients with targeted BRAF and MEK inhibitors more consistently than ever before. At the same time, immune checkpoint inhibitors that target CTLA-4 and PD-1 pathways have become foundational for durable responses in a broad swath of patients, prompting a reassessment of how and when to deploy targeted small molecules versus immunotherapies.

These clinical advances have been paralleled by strategic changes in drug development and commercialization. Companies increasingly pursue combination regimens that strategically pair kinase inhibitors with immune-modulating agents to extend response duration and overcome adaptive resistance. Regulatory agencies have signaled flexibility for accelerated pathways when clear benefit is demonstrated, while emphasizing post-approval evidence generation. Payers and health systems are responding by demanding more robust comparative effectiveness and safety data, which in turn is shaping evidence generation plans from Phase II onward. Together, these shifts compel manufacturers and providers to adopt integrated approaches that coordinate diagnostics, therapy sequencing, and longitudinal patient management to achieve both clinical and economic value.

A strategic analysis of how U.S. tariff adjustments in 2025 can ripple across supply chains, procurement practices, and clinical access for melanoma therapies

Trade policy developments and tariff adjustments can exert outsized effects on global pharmaceutical supply chains, manufacturing economics, and distribution strategies. In 2025, changes in U.S. tariff policy have the potential to influence the melanoma therapeutics ecosystem through multiple, interacting channels, from upstream active pharmaceutical ingredient sourcing to downstream distribution costs and procurement behavior by hospital systems.

Manufacturers that rely on cross-border sourcing of raw materials and finished dosage forms may encounter higher input costs and longer lead times, forcing recalibration of inventory strategies and contract manufacturing relationships. In response, some companies may accelerate reshoring and dual-sourcing initiatives to mitigate exposure, but such transitions typically require capital investment and regulatory coordination. For distributors and hospital pharmacies, even modest increases in transportation and customs-related expenses can translate into tighter formulary negotiations and renewed focus on procurement efficiency. This pressure can also magnify the importance of strategic contracting for high-cost oncology agents, including increased use of outcomes-based arrangements or capped-reimbursement models.

Clinicians and trial sponsors should anticipate operational ripple effects as well. Delays in importation of specialized compounds, diagnostic kits, and supportive care products could affect trial enrollment timelines and real-world access to combination regimens. Regulatory and commercial leaders must therefore integrate trade-policy scenarios into contingency planning, supplier diversification, and pricing strategies to preserve continuity of care and maintain competitive positioning in a shifting policy environment.

A multidimensional segmentation perspective that links mechanism, administration route, treatment line, distribution pathway, and care setting to clinical and commercial imperatives in melanoma therapy

Understanding the market requires careful segmentation by mechanism of action, route of administration, treatment line, distribution channel, and end user, because each axis drives different clinical decision points, commercial levers, and operational challenges. Mechanism of action divides therapies into BRAF inhibitors, CTLA-4 inhibitors, MEK inhibitors, and PD-1 inhibitors, with the BRAF inhibitors category further represented by agents such as dabrafenib, encorafenib, and vemurafenib, the CTLA-4 class exemplified by ipilimumab, the MEK class including binimetinib, cobimetinib, and trametinib, and the PD-1 class typified by nivolumab and pembrolizumab. Each of these molecular classes influences patient selection, toxicity management, and combination strategy differently, and their competitive dynamics reflect differential patent landscapes, label indications, and clinical maturity.

Route of administration also shapes care pathways, with intravenous therapies imposing clinic-based infusion resources and monitoring demands while oral agents shift adherence and dispensing responsibilities to outpatient settings. Treatment line segmentation into first line, second line, and third line and beyond determines reimbursement pathways, sequencing logic, and the comparative evidence required for formulary placement. Distribution channels such as hospital pharmacy, online pharmacy, and retail pharmacy each bring distinct procurement models, inventory turnover characteristics, and patient access considerations. End users span ambulatory surgical centers, hospitals, and oncology centers, and operational realities at each site-ranging from infusion capacity to integrated multidisciplinary care-drive adoption patterns and patient throughput. Synthesizing these segmentation lenses reveals where clinical need, logistical capability, and commercial strategy intersect to create pockets of unmet need and competitive advantage.

A regional intelligence briefing that identifies distinct regulatory, reimbursement, and access dynamics across the Americas, EMEA, and Asia-Pacific and their implications for strategy

Regional dynamics play a pivotal role in shaping access, regulatory strategy, and commercial prioritization for targeted melanoma therapies. In the Americas, established regulatory frameworks and high adoption of precision diagnostics support rapid uptake of approved targeted agents and immunotherapies, yet heterogeneity in payer coverage and state-level procurement policies can create access variability. Manufacturers operating in this region must therefore tailor reimbursement dossiers and real-world evidence generation to regional payer expectations while addressing disparities in diagnostic availability.

Across Europe, the Middle East, and Africa, regulatory pathways vary widely and national health technology assessment processes exert strong influence over adoption timelines and pricing negotiations. Stakeholders in these markets face a dual challenge: harmonizing clinical data to meet multiple assessment bodies while deploying pricing strategies that reflect differential ability-to-pay and procurement mechanisms. In the Asia-Pacific region, a combination of accelerating oncology infrastructure, growing investment in molecular diagnostics, and diverse reimbursement environments creates both high-growth opportunity and operational complexity. Market entrants in Asia-Pacific must navigate country-specific regulatory requirements, local clinical practice patterns, and partnerships that facilitate distribution and diagnostic integration. Taken together, regional differentiation underscores the need for tailored market access strategies, adaptive supply chain planning, and localized evidence generation to translate scientific advances into patient impact.

An informed appraisal of how leading biopharma companies combine translational science, diagnostics partnerships, and supply resilience to sustain leadership in melanoma therapeutics

Leading companies in the melanoma targeted therapy space demonstrate a blend of deep clinical expertise, focused R&D investment, and strategic collaborations. Industry leaders leverage strong translational platforms to advance novel BRAF and MEK inhibitor chemotypes, while also investing substantially in immune-oncology programs that complement targeted approaches. Many firms adopt combination development frameworks that intentionally pair kinase inhibitors with checkpoint inhibitors to address mechanisms of resistance and improve durability of response.

Commercial strategies among these companies emphasize alignment between diagnostic commercialization and therapeutic rollout, recognizing that companion diagnostics are essential for optimal patient selection. Partnerships with diagnostic providers, academic centers, and contract research organizations accelerate clinical enrollment and post-market evidence gathering. Manufacturing and supply-chain resilience have become differentiators, with companies targeting regional capacity expansion and contract manufacturing diversification to reduce disruption risk. Intellectual property strategies focus on lifecycle management through label expansions, next-generation compounds with improved safety or specificity, and formulation innovations that support outpatient administration. Collectively, these corporate behaviors illustrate how integrated scientific, regulatory, and commercial capabilities translate into sustained market relevance and clinical impact.

A pragmatic and prioritized set of strategic actions for drug developers, payers, and providers to translate clinical breakthroughs into durable patient outcomes and commercial viability

Industry leaders should adopt a set of targeted actions that reconcile scientific opportunity with commercial realities. First, aligning clinical development with robust biomarker strategies will be essential to maximize responder identification and to support payer conversations about value. Sponsors should design trials that capture not only tumor response but also durability and quality-of-life endpoints that matter to clinicians and payers. Second, pursuing strategic combinations with clear mechanistic rationale can extend clinical benefit, but such programs must integrate toxicity mitigation plans and real-world implementation pathways.

Third, companies should proactively shore up supply chain resilience by diversifying raw-material sources and expanding regional manufacturing capacity to insulate commercial continuity from policy or logistical shocks. Fourth, engaging early with payers and health technology assessors through transparent evidence-generation plans will reduce time-to-access and facilitate innovative contracting approaches. Finally, providers and health systems should invest in diagnostic infrastructure and care coordination to ensure that advances in targeted therapy translate into consistent, equitable clinical outcomes. Together, these actions will help stakeholders convert scientific breakthroughs into sustainable patient benefit and commercial success.

A transparent explanation of the mixed-methods research approach combining primary expert interviews, secondary literature validation, and triangulated synthesis for robust insights

The research methodology underpinning this executive summary integrates primary qualitative inquiry with rigorous secondary-source validation and iterative triangulation. Primary research consisted of in-depth interviews with clinical investigators, oncology pharmacists, hospital formulary managers, and business leaders to surface real-world adoption drivers, operational constraints, and unmet needs. Secondary research drew on peer-reviewed literature, regulatory guidance documents, trial registries, and corporate filings to construct a comprehensive evidence base and to validate assertions derived from primary interviews.

Data synthesis involved cross-referencing clinical trial outcomes with regulatory milestones and published safety profiles to identify durable signals and persistent knowledge gaps. Where appropriate, expert opinion was used to contextualize emerging trends and to interpret complex interactions between therapeutic mechanisms and clinical practice. Quality assurance steps included source triangulation, expert validation of key findings, and review cycles to ensure clarity and factual accuracy. Limitations of the methodology are acknowledged, including potential selection bias in interview sampling and the dynamic nature of regulatory and clinical environments that can introduce new data post-analysis. Nonetheless, the mixed-methods approach provides a robust foundation for strategic insight and operational planning.

A concise concluding synthesis that ties molecular innovation, diagnostic integration, and operational readiness to practical paths for accelerating patient benefit in melanoma care

In conclusion, targeted therapy for melanoma now sits at the intersection of molecular precision and immune modulation, creating complex but tractable strategic imperatives for stakeholders. Advances in BRAF and MEK inhibition alongside CTLA-4 and PD-1 pathway modulation have established multiple therapeutic pillars, and the emerging focus on combination regimens seeks to extend the benefits of each class while managing overlapping toxicities. Commercially, the integration of diagnostics, evidence generation, and supply resilience will differentiate successful programs from those that struggle to achieve broad, equitable uptake.

Looking forward, leaders who align clinical development with payer evidence needs, invest in diagnostic and distribution infrastructure, and adopt flexible manufacturing and contracting approaches will be best positioned to convert scientific promise into consistent patient impact. Operational readiness, transparent engagement with regulatory and health technology assessment bodies, and a commitment to rigorous post-approval evidence will be the levers that determine how rapidly innovation translates into standard-of-care practice. The path from molecule to meaningful, durable patient benefit is navigable, but it requires coordinated action across scientific, regulatory, and commercial domains.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Targeted Therapy Drugs for Melanoma Market, by Mechanism Of Action

  • 8.1. BRAF Inhibitors
    • 8.1.1. Dabrafenib
    • 8.1.2. Encorafenib
    • 8.1.3. Vemurafenib
  • 8.2. CTLA-4 Inhibitors
  • 8.3. MEK Inhibitors
    • 8.3.1. Binimetinib
    • 8.3.2. Cobimetinib
    • 8.3.3. Trametinib
  • 8.4. PD-1 Inhibitors
    • 8.4.1. Nivolumab
    • 8.4.2. Pembrolizumab

9. Targeted Therapy Drugs for Melanoma Market, by Route Of Administration

  • 9.1. Intravenous
  • 9.2. Oral

10. Targeted Therapy Drugs for Melanoma Market, by Treatment Line

  • 10.1. First Line
  • 10.2. Second Line
  • 10.3. Third Line And Beyond

11. Targeted Therapy Drugs for Melanoma Market, by Distribution Channel

  • 11.1. Hospital Pharmacy
  • 11.2. Online Pharmacy
  • 11.3. Retail Pharmacy

12. Targeted Therapy Drugs for Melanoma Market, by End User

  • 12.1. Ambulatory Surgical Center
  • 12.2. Hospital
  • 12.3. Oncology Center

13. Targeted Therapy Drugs for Melanoma Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Targeted Therapy Drugs for Melanoma Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Targeted Therapy Drugs for Melanoma Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Targeted Therapy Drugs for Melanoma Market

17. China Targeted Therapy Drugs for Melanoma Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Amgen Inc.
  • 18.6. AstraZeneca PLC
  • 18.7. Bayer AG
  • 18.8. Bristol Myers Squibb Company
  • 18.9. Eli Lilly and Company
  • 18.10. GlaxoSmithKline plc
  • 18.11. Johnson & Johnson Services, Inc.
  • 18.12. Merck & Co., Inc.
  • 18.13. Novartis AG
  • 18.14. Pfizer Inc.
  • 18.15. Regeneron Pharmaceuticals, Inc.
  • 18.16. Roche Holding AG
  • 18.17. Sanofi S.A.

LIST OF FIGURES

  • FIGURE 1. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MECHANISM OF ACTION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY TREATMENT LINE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY BRAF INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY BRAF INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY BRAF INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY BRAF INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY DABRAFENIB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY DABRAFENIB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY DABRAFENIB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY ENCORAFENIB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY ENCORAFENIB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY ENCORAFENIB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY VEMURAFENIB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY VEMURAFENIB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY VEMURAFENIB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY CTLA-4 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY CTLA-4 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MEK INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MEK INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MEK INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MEK INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY BINIMETINIB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY BINIMETINIB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY BINIMETINIB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY COBIMETINIB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY COBIMETINIB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY COBIMETINIB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY TRAMETINIB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY TRAMETINIB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY TRAMETINIB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY PD-1 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY PD-1 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY PD-1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY NIVOLUMAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY NIVOLUMAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY NIVOLUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY PEMBROLIZUMAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY PEMBROLIZUMAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY PEMBROLIZUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY FIRST LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY SECOND LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY THIRD LINE AND BEYOND, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY THIRD LINE AND BEYOND, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY THIRD LINE AND BEYOND, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY AMBULATORY SURGICAL CENTER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY AMBULATORY SURGICAL CENTER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY AMBULATORY SURGICAL CENTER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY ONCOLOGY CENTER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY ONCOLOGY CENTER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY ONCOLOGY CENTER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY BRAF INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MEK INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY PD-1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY BRAF INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MEK INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY PD-1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY BRAF INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MEK INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY PD-1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 103. LATIN AMERICA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY BRAF INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MEK INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY PD-1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY BRAF INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MEK INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY PD-1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. MIDDLE EAST TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 127. MIDDLE EAST TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY BRAF INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 128. MIDDLE EAST TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MEK INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 129. MIDDLE EAST TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY PD-1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 130. MIDDLE EAST TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 131. MIDDLE EAST TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 132. MIDDLE EAST TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 133. MIDDLE EAST TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 134. AFRICA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. AFRICA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 136. AFRICA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY BRAF INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 137. AFRICA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MEK INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 138. AFRICA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY PD-1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 139. AFRICA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 140. AFRICA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 141. AFRICA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 142. AFRICA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY BRAF INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MEK INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY PD-1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 149. ASIA-PACIFIC TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 150. ASIA-PACIFIC TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 153. ASEAN TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. ASEAN TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 155. ASEAN TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY BRAF INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 156. ASEAN TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MEK INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 157. ASEAN TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY PD-1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 158. ASEAN TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 159. ASEAN TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 160. ASEAN TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 161. ASEAN TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 162. GCC TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. GCC TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 164. GCC TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY BRAF INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 165. GCC TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MEK INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 166. GCC TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY PD-1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 167. GCC TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 168. GCC TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 169. GCC TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 170. GCC TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPEAN UNION TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPEAN UNION TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPEAN UNION TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY BRAF INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPEAN UNION TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MEK INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPEAN UNION TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY PD-1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPEAN UNION TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPEAN UNION TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPEAN UNION TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPEAN UNION TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 180. BRICS TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. BRICS TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 182. BRICS TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY BRAF INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 183. BRICS TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MEK INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 184. BRICS TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY PD-1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 185. BRICS TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 186. BRICS TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 187. BRICS TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 188. BRICS TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 189. G7 TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. G7 TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 191. G7 TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY BRAF INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 192. G7 TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MEK INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 193. G7 TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY PD-1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 194. G7 TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 195. G7 TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 196. G7 TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 197. G7 TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 198. NATO TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. NATO TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 200. NATO TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY BRAF INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 201. NATO TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MEK INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 202. NATO TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY PD-1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 203. NATO TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 204. NATO TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 205. NATO TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 206. NATO TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 207. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 208. UNITED STATES TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 209. UNITED STATES TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 210. UNITED STATES TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY BRAF INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 211. UNITED STATES TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MEK INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 212. UNITED STATES TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY PD-1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 213. UNITED STATES TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 214. UNITED STATES TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 215. UNITED STATES TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 216. UNITED STATES TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 217. CHINA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 218. CHINA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 219. CHINA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY BRAF INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 220. CHINA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MEK INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 221. CHINA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY PD-1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 222. CHINA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 223. CHINA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 224. CHINA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 225. CHINA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)